

KRAS	ALK	MYD88	NTRK1	PTEN
BRAF	NRAS	PIK3CA	BCR	ROS1
JAK2	RUNX1	PD-L1	ABL	P53
EGFR	MET	RET	HER2	SMAD4

Research & Pharma Services

Innovative assays that help answer your most challenging genomic questions – comprehensively

Why GTC:

- Unique menu offering numerous innovative NGS applications
- Rapid turnaround time
- Project scalability
- Robust AI and deep learning platform to help with report interpretation
- World-class expertise in both hematologic cancers, solid tumors, and immuno-oncology
- Access to over 100,000 data records

Genomic Testing Cooperative is a unique provider of biomarker data through our comprehensive genomic profiling of DNA and RNA.

GTC's testing is standardized using next-generation sequencing to provide the most complete picture of a patient's tumor biology and actionable biomarkers. We have data on both solid and hematologic neoplasms. Our testing and collaborations allow us to provide data points not typically available from other laboratories, which are extremely valuable and rare.

Types of data we can provide

Biomarker data

- FDA-approved
- Standard of care
- Clinical evidence
- Biological relevance
- Other

Lab data

- ICD-10 codes
- Sample type
- Body site
- Order date
- QNS/TNP info


Clinical data*

- Presentation data
- Outcome data
- Treatment data
- Lines of therapy
- Demographic info

* Limited to a subset of patient samples

Areas where we collaborate

- Clinical trial enrollment
- Biomarker frequency
- Custom data solutions



- Retrospective trials – Prospective trials – CDX
- Comprehensive DNA/RNA sequencing applications paired with AI analysis tools
- IHC Assays



Genomic Testing Cooperative, LCA
 25371 Commercentre Dr, Lake Forest, CA 92630
 Tel: 1-949-540-9421 | Fax: 1-949-301-9719
 Toll-Free: 1-866-484-8870





Available Tests	GTC-Solid Tumor Profile PLUS™	Liquid Trace® Solid Tumor	GTC-Solid Tumor Profile™
Genes	>400/>1600	>300/>1600	>400
TAT	🕒 5-10 Days	🕒 5-7 Days	🕒 5-7 Days
Indications	All solid tumors: Detect known (ALK, RET, ROS1, NTRK, etc.) and novel fusions, Exon skipping (MET exon 14), PD-L1 levels, ERBB2 (low HER2) cut-offs and alternative splicing. Chromosomal translocations and amplifications. Viral EBV, HPV, TTV, and HTLV1 testing. HLA genotyping, TMB, MSI, HRD T- & B-cell clonality analysis	All solid tumors: Detect known (ALK, RET, ROS1, NTRK, etc.) and novel fusions, Exon skipping (MET exon 14), PD-L1 levels, ERBB2 (low HER2) cut-offs and alternative splicing. Chromosomal translocations and amplifications. Viral EBV, HPV, TTV, and HTLV1 testing. HLA genotyping. T- & B-cell clonality analysis	All solid tumors: Full exon sequencing in 434 genes includes mutations, indels, copy number variation and chromosomal structural abnormalities, TMB, MSI, HRD, HRR
Sample Type	FFPE	Peripheral Blood, Plasma, CSF	FFPE
Sample Requirements	1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative	Peripheral blood: 8-10 mL. EDTA tube Plasma: 5 mL CSF: 7-10 mL Clear tube	1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
Results Reported	DNA + RNA	DNA + RNA	DNA



Available Tests	GTC-Hematology Profile PLUS™	Liquid Trace® Hematology	GTC-Hematology Profile™
Genes	>300/>1600	>300/>1600	>300
TAT	🕒 7-10 Days	🕒 5-7 Days	🕒 5-7 Days
Indications	All hematologic neoplasms including lymphomas, myelomas, and leukemias Includes IgVH Chromosomal abnormalities, translocations and gene amplifications Viral EBV, HPV and TTV testing. HLA genotyping. T- & B-cell clonality analysis	All hematologic neoplasms including lymphomas, myelomas, leukemias, VEXAS syndrome, EBV, HPV and TTV Chromosomal abnormalities, translocations and gene amplifications Replacement for bone marrow aspirations and biopsy. Monitoring therapy and response. Detection of minimal residual disease (MRD), HLA genotyping, T- & B-cell clonality analysis	Detects various abnormalities in hematologic neoplasms including: Chromosomal abnormalities, Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasms (MPN), Distinguish Clonal Hematopoiesis of Indeterminate Potential (CHIP) VEXAS Disease
Sample Type	Bone marrow, Peripheral blood, Fresh tissue	Peripheral Blood, Plasma, CSF	Bone marrow, Peripheral blood, Fresh tissue
Sample Requirements	Bone marrow: 2mL. Peripheral blood: 5 mL. EDTA tube preferred FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative	Peripheral blood: 8-10 mL. EDTA tube preferred* Plasma: 5 mL CSF: 7-10mL (clear Tube) Samples received beyond 72 hours may include only DNA results	Bone marrow: 2mL. Peripheral blood: 5 mL. EDTA tube preferred FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
Results Reported	DNA + RNA	DNA + RNA	DNA



Solid Tumor



Hematologic Malignancies




Liquid Biopsy



Molecular and Genomic Assays



AI Algorithms



IHC



Customized Assays

Solid Tumor Profile Plus

Pan tumor assay focused on solid tumors

- >400 DNA genes and >1600 RNA genes
- Covers major biomarkers including MSI, TMB, HRD and others
- Detects chromosomal structural changes
- Reliable fusion detection
- Alternative splicing
- Gene expression
- Exon skipping
- Immune profiling
- HLA expression and genotyping
- T-cell & B-cell clonality analysis
- Viral EBV, HPV, TTV, and HTLV-1 testing

Liquid Trace™ (cfDNA and cfRNA)

- Pan tumor assay for both solid tumors and hematologic malignancies
- >300 DNA genes and >1600 RNA genes
- Reliable fusion detection of both known and novel genes
- Covers biomarkers such as HRR, PD-L1, HER2 and more
- Viral EBV, HPV, TTV, and HTLV-1 testing
- HLA expression and genotyping
- Tumor mutation burden (TMB), microsatellite instability (MSI), and homologous recombination deficiency (HRD)
- Detection of minimal residual disease in solid tumors and hematologic malignancies
- Quantitative monitoring of T-cell & B-cell clonality

Hematology Profile Plus

Pan tumor assay focused on hematologic malignancies

- >300 DNA genes and >1600 RNA genes
- Classifies all subtypes of leukemia, lymphomas, myelomas, MDS, VEXAS, CHIP and more
- AML
- CMML
- Detect chromosomal structural changes and chromosomal rearrangements
- Gene expression
- HLA expression and genotyping
- Quantitative monitoring of T-cell & B-cell clonality

AI Algorithms

GTC offers several world class AI software's available for your research and clinical trial projects with multiple publications in top journals. Our AI tools can assist with:

- Picking the correct cut-offs for biomarkers
- Identify responders from non-responders
- Other critical testing algorithms
- Our AI software's can be customized and tuned to work with any assay
- Correlate NGS to other methodologies like Flow, FISH, and IHC

Immunohistochemistry (IHC)

GTC has added Immunohistochemistry (IHC) testing to complement our next-gen sequencing capabilities. We can bring up an antibody or assay to use in your research project. Our NGS can also do a comparison of the IHC and NGS findings.

Capabilities include:

- Histology
- Custom IHC
- Image analysis

Customized Assays

Genomic Testing Cooperative (GTC) offers all types of sequencing services for research projects and clinical trials. We provide a wide range of capabilities from Sanger sequencing to next generation sequencing. All projects are performed in our CAP and CLIA accredited laboratory by Clinical Laboratory Specialists (CLS).

We can provide several standard tumor profiling panels or collaborate on custom panel development for projects in the field of oncology and immuno-oncology. All studies have optional bioinformatics support and access to our deep learning tools or GTC can deliver raw data files for interpretation with your own tools.

Types of Pharma and Research Support Services We Offer:

- Next-gen sequencing
- Sanger sequencing
- RNA-analysis
- Solid tumor research
- Hematology research
- Liquid biopsy
- Custom assay development
- AI analysis
- Bioinformatics support
- CDx development
- Biomarker discovery

Global capabilities for clinical trials through our partnership with Labor Dr. Wisplinghoff

Use Liquid Trace on CSF for CNS tumors
CSF is a very good source of liquid biopsies in primary and metastatic brain tumors

